Examples of using Rasitrio in English and their translations into German
{-}
-
Colloquial
-
Official
-
Ecclesiastic
-
Medicine
-
Financial
-
Ecclesiastic
-
Political
-
Computer
-
Programming
-
Official/political
-
Political
What is Rasitrio?
What Rasitrio is used for.
Information on Rasitrio.
How is Rasitrio used?
Other information about Rasitrio.
How does Rasitrio work?
If you forget to take Rasitrio.
Rasitrio 150 mg/5 mg/12.5 mg film-coated tablets are violet white, oval tablets, with“YIY” debossed on one side and“NVR” on the other.
Other medicines and Rasitrio.
Rasitrio is not recommended for mothers who are breast-feeding, and your doctor may choose another treatment for you if you wish to breast-feed.
Your doctor will carefully consider whether Rasitrio is suitable for you.
Rasitrio 300 mg/5 mg/25 mg film-coated tablets are pale orange-brown, oval tablets, with“OIO” debossed on one side and“NVR” on the other.
In patients≥65 years the incidence was 10.2% with Rasitrio versus up to 5.4% with dual combinations.
Rasitrio is contraindicated in hypertensive patients with severe renal impairment(GFR< 30 ml/min/1.73 m2) or anuria see sections 4.2. and 4.3.
There is evidence of an increased risk of adverse events related to hypotension in patients aged 65 years orolder treated with Rasitrio.
The strength of the Rasitrio tablet that the patient takes depends on the doses of aliskiren, amlodipine and hydrochlorothiazide that they received previously.
Patients aged 65 years old or over,are more susceptible to hypotension-related adverse reactions following treatment with Rasitrio see sections 4.2, 4.8, 5.1 and 5.2.
Studies also showed that the active substances in Rasitrio are absorbed in the body in the same way as the active substances when given as separate tablets.
Rasitrio was associated with a significant reduction in plasma renin activity(PRA)(-34%) from baseline while the dual combination of amlodipine with hydrochlorothiazide increased PRA +170.
The adverse reactions previously reported with one of the individual components of Rasitrio(aliskiren, amlodipine and hydrochlorothiazide) and listed in the respective paragraphs on the individual components may occur with Rasitrio.
When Rasitrio is used in patients with renal impairment, periodic monitoring of serum electrolytes including potassium, creatinine and uric acid serum levels is recommended.
In a randomised, double blind, active controlled, 36-week study in elderly patients whose blood pressure was not controlled with aliskiren/HCTZ 300/25 mg(SBP≥140 mmHg), clinically meaningful further BP reduction was seen atweek 36 endpoint for patients who received Rasitrio at a dose of 300/10/25 mg from reductions in msSBP/msDBP of 15.0/8.6 mmHg at week 22 to reductions of 30.8/14.1 mmHg at week 36 endpoint.
Rasitrio is used to treat high blood pressure in adult patients who have their blood pressure already controlled by aliskiren, amlodipine and hydrochlorothiazide taken as separate medicines given at the same time.
In hypertensive patients, once-daily administration of Rasitrio provided clinically meaningful reductions in both systolic and diastolic blood pressure that were maintained over the entire 24-hour dose interval.
Rasitrio was studied in a double-blind, randomised, active-controlled study in 1,181 patients of which 773 were classified as moderately hypertensive(msSBP 160-180 mmHg) and 408 as severely hypertensive(msSBP> 180 mmHg) at baseline.
Rasitrio is not recommended in early pregnancy, and must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if used at that stage see Pregnancy section.
Rasitrio is indicated for the treatment of essential hypertension as substitution therapy in adult patients whose blood pressure is adequately controlled on the combination of aliskiren, amlodipine and hydrochlorothiazide given concurrently at the same dose level as in the combination.
The use of Rasitrio in patients aged 75 years or older should be restricted to patients for whom blood pressure control has been established for the free combination of aliskiren, amlodipine and hydrochlorothiazide given concurrently without accompanying safety concerns, in particular hypotension.
Rasitrio combines three antihypertensive active substances with complementary mechanisms to control blood pressure in patients with essential hypertension: aliskiren belongs to the direct renin inhibitor class, amlodipine to the calcium channel blocker class and hydrochlorothiazide to the thiazide diuretics class.
Do not take Rasitrio if you are allergic to aliskiren, to amlodipine, to other dihydropyridine-derived medicines(known as calcium channel blockers), to hydrochlorothiazide, to sulphonamide-derived medicines(medicines used to treat chest or urinary infections) or to any of the other ingredients of this medicine listed in section 6.
